ZERIA PHARMACEUTICAL CO., LTD. 健康づくりは 幸せづくり
Making Health
is making happiness
69th
Business Report
From April 1st, 2022 to March 31st, 2023
Securities Code•4559
Contents
To Our Shareholders…………………………………………… P.1
Summary of Our Business Operations (Consolidated)… …… P.3
Status of Research and Development………………………… P.5
Research and Development Pipeline… ……………………… P.6
Status of Production and Distribution /
Outlook for Fiscal Year 2023… ……………………………… P.7
Special Offers to Our Shareholders…………………………… P.8
Topics…………………………………………………………… P.9
Financial Statements (Consolidated)… ……………………… P.11
Company Information… ……………………………………… P.13
Share Information……………………………………………… P.14
Shareholder Memo
To Our Shareholders
We, Zeria Pharmaceutical Co., Ltd. ("Zeria") would like to express our thanks for your particular support.
We are pleased to report the business results of fiscal year 2022 (69th business operations) for the period from April 1st, 2022 to March 31st, 2023.
Chairman and CEO | President and COO |
Sachiaki Ibe | Mitsuhiro Ibe |
1
During the fiscal year under review, the Japanese economy saw a move toward recovery in private consumption and corporate capital investment as socioeconomic activities progressed toward normalization due to the effects of various policies under coexistence with the novel coronavirus (COVID-19). On the other hand, a full-scale recovery did not occur for the decrease of demand from foreign visitors to Japan due to the spread of infection of COVID-19. Moreover, the future impact on the Japanese economy from factors, such as surging energy and raw materials prices caused by the prolonged invasion by Russia into Ukraine, rising distribution costs, rapid yen depreciation, and a slowdown of the global economy, continues to be increasingly unclear.
In the pharmaceutical industry, the market environment for ethical pharmaceuticals has become even more severe due to strengthening of initiatives to curtail healthcare expenses, such as price revisions on a roughly annual basis and the promotion of the use of generic brand pharmaceuticals, even more than before. The market environment for OTC drugs also remained severe due to increasingly fierce market competition, as well as factors such as stagnant demand from foreign visitors to Japan.
Under such circumstances, the Zeria Group saw remarkable growth in overseas sales in the fiscal year under review, which is the final fiscal year of the 10th Mid-Term Management Plan (fiscal year 2020 to fiscal year 2022), amid the earnest acceleration of global expansion. DIFICLIR, a therapeutic agent for Clostridium difficile infections which is currently being sold primarily in Europe by Tillotts Pharma AG has contributed significantly to the overseas sales. On the other hand, in the domestic market, the Ethical Pharmaceuticals Business struggled due to the impact of price revisions, and the Consumer Healthcare Business was also not enough to produce sufficient results overall while it followed a track of recovery due to increased sales of the Hepalyse range and other drugs.
As a result of these activities, net sales for the current fiscal year were 68,383 million yen, up 14.9% from the previous fiscal year. Regarding profits, operating profit was 9,014 million yen, up 41.6% from the previous fiscal year, ordinary profit was 7,579 million yen, up 27.7% from the previous fiscal year, and profit attributable to owners of parent was 6,195 million yen, up 56.4% from the previous fiscal year, resulting in record highs in both net sales and profit.
In the current fiscal year, the overseas sales to net sales ratio was 47.4%, compared with 41.4% in the previous fiscal year.
Furthermore, amid the taking of proactive initiatives in M&A and alliances to strengthen the Zeria Group's business base, we were transferred approval from Astellas Pharma Inc. for the manufacturing and marketing of DIFICLIR, a therapeutic agent for Clostridium difficile infections, in Japan in April 2023 and commenced its sale (domestic sales name: Dafclir).
Net sales | Operating profit ( | )/Ordinary profit ( | )/ | |||
Profit attributable to owners of parent ( | ) | |||||
80,000
(Unit: ¥million)
10,000 | (Unit: ¥million) |
9,014 | |
68,383 | |
60,000 | 59,532 |
52,757 | |
40,000 | |
20,000 | |
0 |
Fiscal Year 2020 Fiscal Year 2021 Fiscal Year 2022
8,000 | 7,579 | ||||||||||||||||||||
6,366 | 5,935 | ||||||||||||||||||||
6,000 | 6,195 | ||||||||||||||||||||
4,000 | 3,475 3,208 | 3,961 | |||||||||||||||||||
3,143 | |||||||||||||||||||||
2,000 | |||||||||||||||||||||
0 |
Fiscal Year 2020 Fiscal Year 2021 Fiscal Year 2022
2
Summary of Our Business Operations (Consolidated)
▶Net sales | ||||||||
¥43,145million | ||||||||
up 16.6% | ||||||||
from the previous fiscal year | ||||||||
▶Net sales of major products
Consumer | |||
Healthcare | |||
Asacol | Business | ||
63.1%
(Net sales
composition ratio)
DIFICLIR
Entocort
Ethical Pharmaceuticals Business
As for the main product, Asacol, a therapeutic agent for ulcerative colitis, sales in the domestic market faced challenging circumstances, owing to the impact of the price revisions and the competitive products. Despite this, sales increased overall as a result of strong performance in regions such as Northern Europe and the UK due to growth in sales of Asacol 1600 mg in overseas markets. Sales of Entocort (domestic sales name: Zentacort), an inflammatory bowel disease therapeutic agent, increased, as sales grew in various regions including Canada, and also Italy, where we established a local subsidiary in 2021 and transitioned to direct-distribution system. Although a generic drug was launched in some European countries in September 2022, the impact on our financial results for the current fiscal year was negligible. In addition, sales of DIFICLIR, a therapeutic agent for Clostridium difficile infections, achieved a
Acofide
Other
significant sales growth as a result of aggressive investment of sales resources in response to its recommendation as a first-line drug in the European guidelines for the treatment of infectious diseases.
Asacol | ¥19.5 billion | ||
DIFICLIR | ¥8.3 billion | ||
Entocort | ¥5.6 billion | ||
Acofide | ¥3.1 billion | ||
▶Consolidated net sales in | |||
Ethical Pharmaceuticals Business (Unit: ¥million) |
50,000 | 43,145 |
40,000 | 37,006 |
30,000 | 29,951 |
20,000 | |
10,000 | |
0 |
Fiscal Year 2020 | Fiscal Year 2021 | Fiscal Year 2022 |
With regard to Ferinject, an iron deficiency anemia therapeutic agent launched in the domestic market in September 2020, we are working to build the market, particularly in the obstetrics and gynecology and gastroenterology fields.
As a result, net sales in the business amounted to 43,145 million yen (up 16.6% from the previous fiscal year).
3
▶Net sales
¥25,085million | |||||||||||||||||||
up 12.1% | |||||||||||||||||||
from the previous fiscal year | |||||||||||||||||||
▶Net sales of major products | |||||||||||||||||||
Ethical | Hepalyse range | ||||||||||||||||||
Pharmaceuticals | |||||||||||||||||||
Business | Chondroitin | ||||||||||||||||||
range | |||||||||||||||||||
36.7% | |||||||||||||||||||
range | |||||||||||||||||||
(Net sales | WithOne | ||||||||||||||||||
Other | |||||||||||||||||||
composition ratio) | |||||||||||||||||||
Hepalyse range | ¥9.8 billion | |||
Chondroitin range | ¥5.4 billion | |||
WithOne range | ¥1.2 billion | |||
▶Consolidated net sales in | ||||
Consumer Healthcare Business | (Unit: ¥million) |
40,000 | |||
30,000 | 25,085 | ||
22,648 | 22,370 | ||
20,000 | |||
10,000 | |||
0 | Fiscal Year 2020 | Fiscal Year 2021 | Fiscal Year 2022 |
Consumer Healthcare Business
As for the main product, Hepalyse range, although it continued to be affected by the COVID-19 pandemic and a stagnation in demand from foreign visitors to Japan, its sales increased owing to the recovery trend in the sales of both the pharmaceutical Hepalyse range and the Hepalyse W range for convenience stores. Sales of the Chondroitin range also remained steady due in part to aggressive advertising and promotional investments.
On the other hand, sales of the WithOne range of herbal laxatives struggled due to the impact of competitive products.
We also worked to strengthen our product lineup by launching sales of new products such as Hi Jelly Granules EX, a nutrient tonic that contains royal jelly as the active ingredient, and Viewclear Hi40 active, a chondroitin-content eye drops. We are working to increase brand awareness for Prefemin, a therapeutic agent for premenstrual syndrome (PMS), as the number of stores selling the product is expected to increase because it transferred to a Type-2 OTC drug in April 2023.
As a result, net sales in the business amounted to 25,085 million yen (up 12.1% from the previous fiscal year).
OTC drugs
Hepalyse® W series
4
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ZERIA Pharmaceutical Co. Ltd. published this content on 25 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 July 2023 00:51:07 UTC.
